• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Fortrea Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders

    6/12/25 9:16:55 AM ET
    $FTRE
    Medical Specialities
    Health Care
    Get the next $FTRE alert in real time by email
    ftre-20250610
    0001965040FALSE00019650402025-06-102025-06-100001965040us-gaap:CommonClassAMember2025-06-102025-06-100001965040us-gaap:PreferredClassAMember2025-06-102025-06-10

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

    June 10, 2025
    Date of Report (Date of earliest event reported)

    Fortrea Holdings Inc.
    (Exact Name of Registrant as Specified in its Charter)


    Delaware
    001-41704
    92-2796441
    (State or other jurisdiction of Incorporation)
    (Commission File Number)
    (I.R.S. Employer Identification No.)

    8 Moore Drive
    Durham,
    North Carolina
    27709
    (Address of principal executive offices)
    (Zip Code)

    (Registrant’s telephone number including area code) 877-495-0816

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Exchange Act.
    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common Stock, $0.001 par valueFTREThe Nasdaq Stock Market LLC
    Rights to Purchase Series A Preferred Stock, par value $0.001 per share-The Nasdaq Stock Market LLC
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
    Emerging growth company ☐
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On June 10, 2025, Fortrea Holdings Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders, upon the recommendation of the Company’s Board of Directors (the “Board”), approved the amendment and restatement of the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan (the “Incentive Plan” and, as amended and restated, the “A&R Incentive Plan”). The A&R Incentive Plan, among other things, increased the number of shares of the Company’s common stock under the Incentive Plan by 6,500,000 shares, provided for minimum vesting periods, provided that no dividends or dividend equivalents payable or credited with respect to restricted stock, restricted stock units or performance share awards or other awards will be paid until the underlying award vests, eliminated liberal share recycling with respect to full-value awards under the Incentive Plan and made certain other administrative changes to the Incentive Plan.

    A summary of the A&R Incentive Plan was also included as part of Proposal 4 in the Company’s Definitive Proxy Statement filed with the Securities and Exchange Commission on April 28, 2025 (the “Proxy Statement”). The foregoing descriptions of the A&R Incentive Plan provided herein and contained in the Proxy Statement are qualified in their entirety by reference to the full text of the A&R Incentive Plan, a copy of which will be filed with the Company’s Quarterly Report on Form 10-Q for the quarter ending June 30, 2025.

    Item 5.07 Submission of Matters to a Vote of Security Holders.

    As of April 17, 2025, the record date for the Annual Meeting, there were 90,540,317 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting. Of these shares, 82,888,659 were present or represented by proxy, which constituted a quorum for the transaction of business at the Annual Meeting. Proxies for the meeting were solicited in accordance with Regulation 14A under the Securities Exchange Act of 1934, as amended. At the Annual Meeting, stockholders voted on the following proposals:

    Proposal 1: Election of Directors

    The following nominees were elected to the Board to serve as Class II Directors until the Company’s 2028 Annual Meeting of Stockholders based on the following votes:

    VotesVotesVotesBroker
    For AgainstAbstainedNon-Votes
    Dr. Amrit Ray 63,349,1667,852,794333,65911,353,040
    Erin L. Russell 68,271,9713,214,08349,56511,353,040
    Machelle Sanders62,641,8948,843,81249,91311,353,040

    Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm

    The appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified based upon the following votes:

    VotesVotesVotes
    For AgainstAbstained
    82,675,784114,33998,536

    Proposal 3: Advisory Vote on the Compensation of the Company’s Named Executive Officers

    The proposal to approve, on an advisory basis, the compensation of the Company’s Named Executive Officers was approved based upon the following votes:

    VotesVotesVotesBroker
    For AgainstAbstainedNon-Votes
    68,050,2813,302,818182,52011,353,040



    Proposal 4: Approval of the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan, as Amended and Restated

    The proposal to amend and restate the Fortrea Holdings Inc. 2023 Omnibus Incentive Plan was approved by the following final voting results:

    VotesVotesVotesBroker
    For AgainstAbstainedNon-Votes
    67,787,6643,586,743161,21211,353,040





    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Fortrea Holdings Inc.
    By:
    /s/ Stillman Hanson
    Name: Stillman Hanson
    Title: General Counsel and Secretary
    Date: June 12, 2025



    Get the next $FTRE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $FTRE

    DatePrice TargetRatingAnalyst
    12/11/2025$21.00Neutral → Buy
    Citigroup
    8/4/2025$9.00Neutral → Outperform
    Robert W. Baird
    5/2/2025$7.00Hold
    Truist
    4/10/2025$6.00Equal Weight → Underweight
    Barclays
    12/11/2024$30.00 → $23.00Buy → Neutral
    Citigroup
    12/6/2024$28.00 → $25.00Outperform → Neutral
    Robert W. Baird
    9/25/2024$25.00 → $21.00Buy → Hold
    Jefferies
    8/8/2024$31.00 → $27.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $FTRE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fortrea upgraded by Citigroup with a new price target

    Citigroup upgraded Fortrea from Neutral to Buy and set a new price target of $21.00

    12/11/25 8:44:49 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea upgraded by Robert W. Baird with a new price target

    Robert W. Baird upgraded Fortrea from Neutral to Outperform and set a new price target of $9.00

    8/4/25 8:16:07 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Truist initiated coverage on Fortrea with a new price target

    Truist initiated coverage of Fortrea with a rating of Hold and set a new price target of $7.00

    5/2/25 8:14:26 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

    DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units ("RSUs") on December 10, 2025, to two newly hired employees. The award consisted of 245,000 RSUs that vest in three equal annual installments starting December 10, 2026, subject to the employee's continuous employment through the applicable vesting date. The RSUs are subject to the terms and conditions of the Company's Amended and Restated 2025 Inducement Award Plan and the award agreements covering the grants. These awards follow Nasdaq Listing Rule 5635(c)(4) and are intended a

    12/10/25 6:00:00 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SCTbio and Fortrea Forge Strategic Collaboration to Accelerate Cell and Gene Therapy Development and Delivery

    PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies. This partnership aims to streamline development, accelerate timelines and bring advanced therapies to patients faster. This collaboration represents a forward-looking model for how CDMOs and CROs can collaborate to deliver synchronized solutions that help to de-risk programs, streamline planning, expedite study setup and optimize cost-efficiency across the entire development lifecy

    12/4/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea to Present at Upcoming Citi and Evercore Healthcare Conferences

    DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December: Citi Global Healthcare Conference (Miami)Date:Tuesday, December 2, 2025Time:1:00 pm ETFormat:Fireside ChatWebcast:FTRE Citi webcast Evercore 8th Annual Healthcare Conference (Miami)Date:Wednesday, December 3, 2025Time:10:50 am ETFormat:Fireside ChatWebcast:FTRE Evercore webcast  The live webcasts and replay of the fireside chats will be accessib

    11/25/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    SEC Filings

    View All

    Fortrea Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure

    8-K - Fortrea Holdings Inc. (0001965040) (Filer)

    11/20/25 4:11:54 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fortrea Holdings Inc.

    SCHEDULE 13G/A - Fortrea Holdings Inc. (0001965040) (Subject)

    11/14/25 11:22:58 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 10-Q filed by Fortrea Holdings Inc.

    10-Q - Fortrea Holdings Inc. (0001965040) (Filer)

    11/5/25 4:05:12 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sharbaugh William J

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    11/24/25 4:03:48 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Sharbaugh William J

    3 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/25/25 5:22:04 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Chief Accounting Officer Parks Robert converted options into 24,934 shares and sold $73,013 worth of shares (7,338 units at $9.95), increasing direct ownership by 1,214% to 19,046 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/17/25 4:16:36 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Russell Erin L bought $100,018 worth of shares (9,854 units at $10.15) (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    9/4/25 4:39:23 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Director Neupert Peter M bought $407,150 worth of shares (62,500 units at $6.51), increasing direct ownership by 175% to 98,132 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    8/11/25 8:21:29 PM ET
    $FTRE
    Medical Specialities
    Health Care

    General Counsel Hanson James S. bought $50,600 worth of shares (2,000 units at $25.30), increasing direct ownership by 37% to 7,475 units (SEC Form 4)

    4 - Fortrea Holdings Inc. (0001965040) (Issuer)

    6/12/24 6:28:42 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Leadership Updates

    Live Leadership Updates

    View All

    Fortrea Appoints Agnieszka Gallagher as General Counsel

    DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M. Gallagher as general counsel. Gallagher is responsible for the Company's legal strategy and operations, serving as corporate secretary, chief compliance officer and as a member of Fortrea's leadership team. She succeeds J. Stillman Hanson, who is leaving the Company after a planned transition period. "Aggie brings broad and deep executive experience in the life sciences and beyond to Fortrea, with a track record of navigating complexity in global companies," said Anshul Thakral, CEO of Fortrea.

    11/17/25 7:00:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints William Sharbaugh to Board of Directors

    DURHAM, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced the appointment of William Sharbaugh to the Company's Board of Directors. Mr. Sharbaugh brings extensive healthcare experience in finance, operations, manufacturing, and quality to the position, having served in executive and board roles during his more than three decades in the pharmaceutical industry. "I'm delighted to welcome Bill to the Fortrea Board, bringing an impressive background in CRO and pharmaceutical operations," said Anshul Thakral, CEO of Fortrea. "He is a highly respected leader, who understands our stakeholders a

    9/22/25 4:30:50 PM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Appoints Tracy Krumme as Senior Vice President, Investor Relations

    DURHAM, N.C., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE), a leading global contract research organization (CRO), today announced the appointment of Tracy Krumme as senior vice president, investor relations, succeeding Hima Inguva in this role, who has decided to pursue other career opportunities. Krumme will report to Chief Financial Officer, Jill McConnell, and lead Fortrea's global investor relations strategy, serving as a key liaison to the investment community. "Tracy is a seasoned executive with the strategic mindset and investor acumen needed as Fortrea enters its next chapter," said McConnell. "She brings not only deep capital markets expertise but also integrity, insi

    8/5/25 6:00:02 PM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Financials

    Live finance-specific insights

    View All

    Fortrea Reports Third Quarter 2025 Results

    For the three months ended September 30, 2025, from continuing operations: Revenues of $701.3 millionGAAP net loss of $(15.9) millionAdjusted EBITDA of $50.7 millionGAAP and adjusted net (loss) income per diluted share of $(0.17) and $0.12, respectivelyBook-to-bill ratio of 1.13x, resulting in 1.07x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,700 million to $2,750 million; narrowing 2025 adjusted EBITDA guidance to a range of $175 million to $195 million DURHAM, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today reported

    11/5/25 6:30:00 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Announces Date for Third Quarter 2025 Financial Results and Conference Call

    DURHAM, N.C., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today announced that it will release its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. Fortrea will host a conference call at 8:00 am ET that day to review its financial results and conduct a question-and-answer session. To participate in the earnings call, participants should register online at the Fortrea Investor Relations website. To avoid potential delays, please join at least 10 minutes prior to the start of the call. The conference call can also be accessed through the following earnings webcast

    10/15/25 7:00:24 AM ET
    $FTRE
    Medical Specialities
    Health Care

    Fortrea Reports Second Quarter 2025 Results

    For the three months ended June 30, 2025, from continuing operations: Revenues of $710.3 millionGAAP net loss of $(374.9) million, inclusive of a non-cash goodwill impairment chargeAdjusted EBITDA of $54.9 millionGAAP and adjusted net (loss) income per diluted share of $(4.14) and $0.19, respectivelyBook-to-bill ratio of 0.79x, resulting in 1.10x book-to-bill for the trailing 12 monthsCost saving initiatives remain on trackRaising 2025 revenue guidance to a range of $2,600 million to $2,700 million; affirming 2025 adjusted EBITDA guidance DURHAM, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fortrea (NASDAQ:FTRE) (the "Company"), a leading global contract research organization (CRO), today rep

    8/6/25 6:30:34 AM ET
    $FTRE
    Medical Specialities
    Health Care

    $FTRE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fortrea Holdings Inc.

    SC 13G - Fortrea Holdings Inc. (0001965040) (Subject)

    11/12/24 9:55:14 AM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    5/28/24 5:10:47 PM ET
    $FTRE
    Medical Specialities
    Health Care

    SEC Form SC 13D/A filed by Fortrea Holdings Inc. (Amendment)

    SC 13D/A - Fortrea Holdings Inc. (0001965040) (Subject)

    2/26/24 7:01:18 PM ET
    $FTRE
    Medical Specialities
    Health Care